We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Centessa Pharmaceuticals PLC | NASDAQ:CNTA | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.36 | -3.16% | 11.04 | 11.08 | 11.67 | 11.61 | 10.95 | 11.42 | 332,516 | 01:00:00 |
FORM 8-K |
England and Wales | 001-04321 | 98-1612294 | ||||||||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Ordinary shares, nominal value £0.002 per share | CNTA | Nasdaq Stock Market, LLC* | ||||||||||||
American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share | CNTA | Nasdaq Stock Market, LLC |
Ordinary Resolutions | For | Against | Withheld | Broker Non-Votes | ||||||||||
To re-appoint as a director Arjun Goyal, M.D., M.Phil., M.B.A., who retires by rotation in accordance with the Company’s articles of association. | 63,746,443 | 484,915 | 97 | — | ||||||||||
To re-appoint as a director Aaron Kantoff, who retires by rotation in accordance with the Company’s articles of association. | 62,865,132 | 1,366,226 | 97 | — | ||||||||||
To re-appoint as a director Samarth Kulkarni, who retires solely for the purpose of rebalancing the rotation of the election of directors in accordance with the Company’s articles of association. | 58,523,637 | 5,707,721 | 97 | — | ||||||||||
To appoint KPMG LLP, a United Kingdom entity, as UK statutory auditors of the Company, to hold office from the conclusion of this Annual General Meeting until the conclusion of the next annual general meeting at which the Company’s annual accounts and reports are laid before the Company. | 64,148,825 | 82,517 | 113 | — | ||||||||||
To ratify the appointment of KPMG LLP, a Delaware limited liability partnership, as the Company’s independent registered public accounting firm, for the financial year ending December 31, 2022. | 64,149,126 | 82,216 | 113 | — | ||||||||||
To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the financial year ending December 31, 2022. | 64,178,794 | 52,518 | 143 | — | ||||||||||
To receive and adopt our U.K. statutory annual accounts and reports for the financial year ended December 31, 2021 and to note that the Company’s directors do not recommend the payment of any dividend for the financial year ended December 31, 2021. | 64,206,658 | 3,867 | 20,930 | — | ||||||||||
To receive and approve, on an advisory basis, the Company’s U.K. statutory directors’ remuneration report for the financial year ended December 31, 2021, which is set forth as Annex A to the attached proxy statement. | 63,872,064 | 47,806 | 311,585 | — | ||||||||||
To receive and approve the Company’s U.K. statutory directors’ remuneration report as set out on pages A-3 to A-16 of the Company’s U.K. statutory directors’ annual report on remuneration set forth in Annex A to the attached proxy statement, which will take effect immediately after the end of the Annual General Meeting. | 63,858,376 | 61,775 | 311,304 | — |
By: | /s/ Saurabh Saha | |||||||
Name: | Saurabh Saha, M.D., Ph.D. | |||||||
Title: | Chief Executive Officer |
1 Year Centessa Pharmaceuticals Chart |
1 Month Centessa Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions